Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

Abstract Background Understanding the impact of the tumor immune microenvironment and BRCA1/2-related DNA repair deficiencies on the clinical activity of immune checkpoint inhibitors may help optimize both patient and treatment selection in metastatic triple-negative breast cancer. In this substudy...

Celý popis

Podrobná bibliografie

Vydáno v:	JNCI : Journal of the National Cancer Institute Ročník 113; číslo 8; s. 1005 - 1016
Hlavní autoři:	Emens, Leisha A, Molinero, Luciana, Loi, Sherene, Rugo, Hope S, Schneeweiss, Andreas, Diéras, Véronique, Iwata, Hiroji, Barrios, Carlos H, Nechaeva, Marina, Nguyen-Duc, Anh, Chui, Stephen Y, Husain, Amreen, Winer, Eric P, Adams, Sylvia, Schmid, Peter
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Oxford University Press 02.08.2021
Témata:	Albumins Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - therapeutic use B7-H1 Antigen - metabolism Biomarkers Humans Lymphocytes, Tumor-Infiltrating - pathology Paclitaxel Triple Negative Breast Neoplasms - pathology Tumor Microenvironment
ISSN:	0027-8874, 1460-2105, 1460-2105
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!